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Poster Session I S2730.005 one sided) but not at 1 year (p 5 0.34, two-sided). There was
no significant difference in mortality rates between the EAP group
and the control group.
Conclusions: Multiple transfusions raise the risk of secondary he-
mochromatosis, a risk factor for infections and increased mortality.
Erythropoietin-assisted phlebotomy is a treatment to prevent the
complications of iron overload in HSCT patients.328
SAFETY AND IMMUNOGENICITY OF HEAT-TREATED ZOSTER VACCINE
(ZVHT) IN ADULTS WITH ALLOGENEIC OR AUTOLOGOUS HEMATOPOI-
ETIC STEM-CELL TRANSPLANTS (HCT)
Winston, D.1, Mullane, K.2, Boeckh, M.3, Zhao, Y.4, Fernsler, D.4,
Manoff, S.4, Annunziato, P.4 1University of California - Los Angeles;
2University of Chicago; 3Fred Hutchinson Cancer Research Center;
4Merck & Co., Inc
Background: Herpes zoster incidence is higher in patients with
a hematopoietic stem cell transplant [HCT] (200 cases/1000 per-
son-years) than in the general population (3-5 cases/1000 per-
son-years). A heat-treated zoster vaccine [ZVHT] was assessed in
adults with allogeneic or autologous HCT.
Methods: Randomized, double-blind, placebo-controlled, multi-
center Phase I study of a 4-dose ZVHT regimen (1 dose pre-HCT;
3 doses post-HCT, each 30 days apart) in adults $ 18 years with
autologous (n 5 50) or allogeneic (n 5 50) HCT. In each group,
40 received ZVHT and 10 placebo (Pbo). Bloodwas collected at base-
line & 28 days after each dose to measure (1) VZV antibody con-
centrations by glycoprotein enzyme-linked immunosorbent assay
(gpELISA), and (2) varicella zoster virus (VZV) T-cell responses
by interferon-gamma enzyme-linked immunospot (IFN-g ELI-
SPOT) assay. All vaccinated patients were evaluated for adverse
events (AEs) through day 28 postdose 4. Immunogenicity analyses
for both HCT groups were exploratory (no pre-specified hypothe-
ses).
Results: ZVHT safety profile was similar to placebo. Injection-site
adverse events (AEs) occurred in 15% of the ZVHT group and
10% of the Pbo group. There were no reported vaccine-related
serious AEs. No patients discontinued due to vaccine-related AEs.
Herpes zoster (PCR positive) occurred in 1 ZVHT and 1 placebo pa-
tient (both autologous HCT patients). There were also 2 patients in
the ZVHT group that had suspected HZ not confirmed by PCR (1 inTable 1. Immunogenicity Results Summary
Allogeneic HCT Autologous HCT
ZVHT Placebo ZVHT Placebo










GMC [28] 13.7 (6.6,28.4) [7] 4 (0.7,22.2) [31] 9.1 (5.2,15.9) [7] 8.6 (2,8,26.1)
Postdose 1
GMC [29] 2.2 (1.1,4.2) [9] 1.1 (0.5,5.5) [24] 10.8 (5.3,22.3) [7] 4.3 (1.7,10.9)
GMFR [20] 0.1 (0.0,0.3) [7] 0.2 (0.1,1.0) [20] 0.4 (0.2,0.9) [7] 0.5 (0.1,2.1)
Postdose 2
GMC [27] 2.6 (1.5,4.4) [8] 1.1 (0.7,1.7) [25] 12.6 (5.6,28.4) [5] 4.8 (0.5,50.0)
GMFR [20] 0.2 (0.2,0.4) [6] 0.4 (0.1,1.8) [18] 0.6 (0.3,1.2) [3] 1.2 (0.0,287.4)
Postdose 3
GMC [22] 2.1 (1.0,4.3) [7] 0.9 (0.6,1.4) [27] 63.3 (33.0,121.3) [5] 2.0 (0.4,9.6)
GMFR [14] 0.1 (0.0,0.5) [6] 0.3 (0.1,1.8) [21] 4.5 (1.7,11.7) [3] 0.1 (0.0,2.5)
Postdose 4
GMC [26] 2.7 (1.5,4.9) [5] 0.5 (0.5,0.5) [24] 92.2 (47.0,180.9) [5] 4.9 (0.8,30.5)
GMFR [17] 0.2 (0.1,0.5) [4] 0.2 (0.0,7.8) [19] 7.6 (2.7,21.7) [4] 0.5 (0.1, 4.7)
N5number of patients vaccinated.
n5number of patients included in analysis.
GMC5geometric mean count.
GMFR5geometric mean fold rise from Day1 (baseline).eachHCT group). No ZVHT recipient had a rash that was PCR pos-
itive for the vaccine strain of VZV.
At baseline, the VZV-specific gpELISA geometric mean titer
(GMT) was 152 (90% CI: 107, 216) in allogenic HCT patients
and 214 (90%CI: 147, 311) in autologous HCT patients. Both mea-
sures decreased Postdose 4: 139 (90% CI: 103, 189) and 196 (90%
CI: 126, 305), respectively. VZV-IFN- g responses are summarized
in the table below.
Conclusion: 4 doses of ZVHT had an acceptable safety profile in pa-
tients undergoingHCT. Significant T-cell responses were elicited in
patients undergoing autologous HCT, but not in patients undergo-
ing allogeneic HCT.
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INCREASED RESTING ENERGY EXPENDITURE IS ASSOCIATED WITH
FAILURE TO THRIVE IN SEVERE COMBINED IMMUNODEFICIENCY
Makhija, M., Barron, M.A., Hagen, L.E.M., Pencharz, P.,
Grunebaum, E., Roifman, C. The Hospital for Sick Children, Toronto,
ON, Canada
Introduction: Patients with Severe Combined Immunodeficiency
(SCID) often suffer from failure to thrive (FTT) caused by chronic
infections, poor energy intake and/or malabsorption. Increased rest-
ing energy expenditure (REE)might also contribute to FTT in these
patients as it does in patients with other immune deficient states in-
cluding HIV and malignancy.
Objectives:Our objectives were to measure REE (MREE) and de-
termine if increased REE (hypermetabolism) is associated with
FTT in SCID patients at diagnosis prior to bone marrow trans-
plantation.
Study Design: REE was measured by indirect calorimetry in 26 pa-
tients with SCID, before BMT conditioning, at a single transplant
center. Predicted REE (PREE) was determined byWHO standards.
MREE. 110% of PREE was classified as hypermetabolism. Other
data collected at diagnosis included FTT status, infectious history,
genotype, phenotype and the feeding methods used.
Results: Fifteen of 26 (57.7%) patients were FTT and 18/26 (69.2%)
were hypermetabolic. Hypermetabolism occurred in 14/15 (93%) pa-
tients with FTT, while only 4/11 (36%) patients without FTThad hy-
permetabolism (P5 0.003).Therewas a significant difference between
the MREE (455 6 169 kcal) and the PREE (333 6 106 kcal) (p\
0.0001). Hypermetabolism was significantly more common in those
between the ages of 3-12 months. Logistic regression was performed
to determine the probability of FTT using the MREE expressed as
a percentage of the PREE for age and gender, adjusted for diarrhea
and pneumonia. An increased probability of FTT was found, if hyper-
metabolism was present, independent of diarrhea and pneumonia.
Eleven of 17 (65%) patients required nasogastric feeding and/or paren-
teral nutrition to meet their energy needs.
Conclusions: Hypermetabolism is common in patients with SCID
in the pre-BMT period and may contribute to the development of
FTT. The hypermetabolism in these patients may necessitate inten-
sive nutrition support.
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EXPERIENCE WITH CMX001, A NOVEL ANTIVIRAL DRUG, FOR CYTO-
MEGALOVIRUS INFECTIONS IN STEM CELL TRANSPLANT PATIENTS
Papanicolau, G.1, Kurtzberg, J.2, Westervelt, P.3, Gea-Banacloche, J.4,
Warlick, E.5, Lanier, R.6, Anderson, M.6, Painter, W.6 1Memorial Sloan
Kettering Cancer Center, New York, NY; 2Duke UniversityMedical Cen-
ter, Durham, NC; 3Washington University School of Medicine, St. Louis,
MO; 4National Cancer Institute, Bethesda, MD; 5University of Minne-
sota, Minneapolis, MN; 6Chimerix, Inc., Durham, NC
Cytomegalovirus (CMV) infections are associated with signifi-
cant morbidity and mortality in the stem cell transplant setting.
CMX001, a lipid conjugate of cidofovir is administered orally
and circulates as the lipid conjugate in plasma; it is efficiently taken
up by target cells and high concentrations of the active antiviral are
achieved intracellularly. We describe the first clinical experiences
in stem cell transplant patients infected with CMV who received
CMX001. The patients had history of AML (3 patients), refractory
lymphoma, multiple myeloma, and severe aplastic anemia, and
sickle cell anemia. Six of the seven patients had received SCT
and the seventh awaited SCT. Treatment with CMX001 was
Table 1. Serum 25 (OH) D2+D3 Level in ng/ml








(n562) (n536) (n539) (n516)
Severe Def. (<10) 0 0 0 0
Moderate Def. (10-20) 16 (25.8%) 6 (16.6%) 4 (10.3%) 3 (18.8%)
Mild Deficiency (21-30) 22 (35.4%) 7 (19.4%) 10 (25.6%) 3 (18.8%)
Sufficient Level (>30) 24 (38.7%) 23 (63.8%) 25 (64.1%) 10 (62.5%)
Tx, Transplant; Def., Deficiency.
S274 Poster Session Iinitiated pre-transplant in one patient, and 21 days to greater than
2 years in six patients (median of 61days).
We analyzed 7 patients with CMV viremia who were treated un-
der emergency IND because of lack of other reasonable therapeutic
options. All 7 patients had failed conventional antiviral therapy: all
patients had received ganciclovir and/or valganciclovir, 6 had re-
ceived foscarnet, and 4 had received CMV IG. The doses of
CMX001 in these patients ranged from 80 mg to 300 mg (approxi-
mately 2 to 4mg/kg); follow-up data was available for at least 4 weeks
in all patients. Virologic response was defined as more than a 90%
reduction (1 log 10) in viral load (VL) and complete response was de-
fined as an undetectable viral load.
The4males and3 females treatedhad amedianage of 55 years (range
11 to 69 years); theywere treatedwithCMX001 for amedian of 88 days
(range 29-131 days). The median reduction in VL was greater than 1.2
log 10 at 4 weeks. A complete response was observed in 3/5 (60%) pa-
tients who did not have mutations in the CMV polymerase UL54
gene; 2/5 had an average reduction in CMV by PCR of 1.2 log 10.
Neither of two patients with a relevant mutation in UL54 (L501F and
A987G) had a 1 log reduction in viremia at the last time point.
Two patients had pre-existing renal insufficiency; no dose adjust-
ment was needed based on kidney function. Four of 7 patients had
GVHD during treatment with CMX001. One patient experienced
C. difficile colitis, one experienced pancytopenia, one with a seizure
disorder experienced seizure, and one experienced severe GVHD.
No trends were observed in SAEs.
This case series demonstrates that CMX001 is a promising thera-
peutic option for the treatment of CMV disease in stem cell trans-
plant patients.
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A PROGNOSTIC INDEX THAT PREDICTS SURVIVAL OF MECHANICALLY
VENTILATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
RECIPIENTS
Solh, M., Oom, S., Isaksson Vogel, R., Shanley, R., Burns, L.J. University
of Minnesota, Minneapolis, MN
Purpose: The overall outcome of hematopoietic cell transplant re-
cipients (HCT) who requiremechanical ventilation (MV) has histor-
ically been poor. However, more recent studies have shown
improved survival. We evaluated the outcome of ventilated adult
HCT recipients at the University of Minnesota and sought a prog-
nostic index to predict 100 day post-MV overall survival (OS) based
on factors present at the time of MV.
Patients andMethods: A retrospective study of patients$ 18 years
of age (n5 1557) who received HCT at the University of Minnesota
between 1998 and 2009. Patients’ demographics and clinical out-
comes were prospectively collected from the transplant database.
Data regarding MV, organ failure and organ failure support were
retrospectively collected from patients’ records. 234 patients (15%)
required MV in the first 100 days post HCT and were divided into
a training set (n156) and a validation set (n 5 78). Multivariate
Cox regression and recursive partitioning were used to build a model
that classified patients into either good (class A) or poor (class B)
prognostic groups. The final model was assessed in the validation set.
Results: MV occurred prior to neutrophil engraftment (ANC $
500/ml x2 days) in 94 patients (40%). 137 patients (59%) were venti-
lated within 30 days of HCT.The 100 day post-MVOSwas 18% for
the total population. Karnofsky score, serum total bilirubin and cre-
atinine levels at time of MV, platelet count and acute GVHD were
predictors of worse OS in the training set. Recursive partitioning
on the training set showed that creatinine\ 2 mg/dl, platelet count
. 20,000/ml and total bilirubin\ 5 mg/dl at time of MV predicted
a good prognostic group (class A) with 38% OS in the training set,
35% in the validation set and 37% in the total population.In con-
trast, the poor prognostic group (class B), had 9% 100 day OS in
the training set, 7% in the validation set and 8% in the total
population. Class A patients were less likely to develop kidney failure
(34% versus 70%, p\ 0.0001), require dialysis (25% versus 41%,
p 5 0.0202) and less likely to develop liver failure (5% versus
38%, p\ 0.0001) during MV.
Conclusion: MV support is justified in HCT recipients with good
prognostic features that are easily identified at the time of ventilation
need. Conversely, initiation of MV is questionable for patients with
poor prognostic features. For more universal use, this prognostic index
requires validation at other centers and in other patient populations.332
VITAMIN D DEFICIENCY IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Desai, S.R.1, Tewari, P.1, Whelan, M.2, Kurtzberg, J.1, Prasad, V.K.1
1Duke University Medical Center, Durham, NC; 2Duke University
Medical Center, Durham, NC
Background:Hematopoietic stem cell transplantation (HSCT)may
increase the risk of Vitamin D deficiency from chemotherapy, radi-
ation, nutritional difficulties, graft versus host disease (GVHD), re-
stricted physical activity and limited sun exposure. Therefore,
defining the extent of this problem is clinically relevant and may
be therapeutically useful.
Methods: HSCT recipients, who were # 18 years of age, trans-
planted at Duke between 01/2007 and 03/2009 and had serum Vita-
min D measured, were included in this retrospective study. Total
numbers of subjects satisfying these criteria were 71 (24 female; 25
non-Caucasian). Diagnoses were malignant in 39 and nonmalignant
in 32 patients. Vitamin D status was defined by serum 25(OH)
D2+D3 levels as follows: severe deficiency,\10ng/ml; moderate de-
ficiency, 10-20ng/ml, mild deficiency, 21-30 ng/ml. Osteopenia was
recorded from X-rays that were performed for any clinical reason
during the study period.
Results: The median (range) age at HSCT was 6.7 years (0.1-18),
weight was 29.1 kg (4-86.4), height was 117.2 cm (54-181), and
post-transplant follow-up duration was 25.3 months (2.6-44.7). At
transplant, 22.5% and 42%of all subjects were below 25th percentile
for weight and height, respectively. Of 71 patients, 61 received mye-
loablative conditioning. Their median in-patient stay was 48 days
(25-140). All subjects had received TPN and the median duration
of TPN therapy was 64 days (range, 16-598). Overall, 46% of sub-
jects had vitamin D deficiency during the study period (details in ta-
ble). Vitamin D deficiency was present in 18 of 24 (75%) subjects
with prolonged diarrhea, in 7 of 11 (64%) subjects on pancreatic en-
zyme therapy, in 13 of 27 (48%) subjects with chronicGVHD, and in21 of 38 (55%) subjects with serum albumin\2.5 gm/dL. Osteope-
nia was seen in 32 (45%) subjects, half of whom had Vitamin D de-
ficiency.
Conclusions:Vitamin D deficiency is prevalent in pediatric patients
undergoing HSCT. Serum levels should be checked prospectively
before and after transplantation, treatment should be administered
for low levels and the clinical impact should be further studied.333
INCIDENCE AND RESPONSE TO TREATMENT OF ADENOVIRUS (ADV) IN-
FECTION WITH CIDOFAVIR (C) IN PEDIATRIC PATIENTS AFTER ALLOGE-
NEIC HCT
Morris, C.L.,Morris, J.D. Loma Linda University Hospital, Loma Linda,
CA; , NC; , CA
ADV infection occurs frequently and has a high mortality after
HCT. The antiviral cidofavir has activity against ADV, but has sig-
nificant renal and marrow toxicity. We report our centers incidence
of ADV and its association with type of transplant and GVHD (clin-
ically significant requiring . 1mg/kg solumedrol for at least 2
weeks). Between August 2002 and June 2010 76 patients received
